Abstract:Background Urolithiasis is a prevalent condition encountered in urology. Over the past decade, its global incidence has been on an upward trajectory; paired with a high recurrence rate, this presents considerable health and economic burdens. Although inflammatory factors are pivotal in the onset and progression of urolithiasis, their causal linkages remain elusive. Method Mendelian randomization (MR) is predicated upon genome-wide association studies (GWASs). It integrates bioinformatics analyses to reveal causal relationships between exposures and outcomes, rendering it an effective method with minimized bias. Drawing from a publicly accessible GWAS meta-analysis comprising 8,293 samples, we identified 41 genetic variations associated with inflammatory cytokines as instrumental variables. Outcome data on upper urinary tract stones, which included renal and ureteral stones (9,713 cases and 366,693 controls), and lower urinary tract stones, including bladder and urethral stones (1,398 cases and 366,693 controls), were derived from the FinnGen Consortium R9 dataset. By leveraging the bidirectional MR methodology, we aimed to decipher the causal interplay between inflammatory markers and urolithiasis. Results Our study comprehensively elucidated the association between genetic inflammatory markers and urolithiasis via bidirectional Mendelian randomization. Post-MR analysis of the 41 genetic inflammation markers revealed that elevated levels of circulating interleukin-2 (IL-2) (OR = 0.921, 95% CI = 0.848–0.999) suggest a reduced risk for renal stone disease, while heightened stem cell growth factor beta (SCGF-β) (OR = 1.150, 95% CI = 1.009–1.310) and diminished macrophage inflammatory protein 1 beta (MIP-1β) (OR = 0.863, 95% CI = 0.779–0.956) levels suggest an augmented risk for lower urinary tract stones. Furthermore, renal stone disease appeared to elevate IL-2 ( β = 0.145, 95% CI = 0.013–0.276) and cutaneous T cell-attracting chemokine (CTACK) ( β = 0.145, 95% CI = 0.013–0.276) levels in the bloodstream, whereas lower urinary tract stones were linked to a surge in interleukin-5 (IL-5) ( β = 0.142, 95% CI = 0.057–0.226), interleukin-7 (IL-7) ( β = 0.108, 95% CI = 0.024–0.192), interleukin-8 (IL-8) ( β = 0.127, 95% CI = 0.044–0.210), growth regulated oncogene alpha (GRO-α) ( β = 0.086, 95% CI = 0.004–0.169), monokine induced by interferon-gamma (MIG) ( β = 0.099, 95% CI = 0.008–0.191) and macrophage inflammatory protein 1 alpha (MIP-1α) ( β = 0.126, 95% CI = 0.044–0.208) levels. Conclusion These discoveries intimate the instrumental role of IL-2 in the onset and progression of upper urinary tract stones. SCGF-β and MIP-1β influence the development of lower urinary tract stones. Urolithiasis also impacts the expression of cytokines such as IL-2, CTACK, IL-5, IL-7, IL-8, GRO-α, MIG, and MIP-1α. There is a pressing need for further investigation to ascertain whether these biomarkers can be harnessed to prevent or treat urolithiasis.

Circulating levels of cytokines and risk of urologic cancers: a two-sample Mendelian randomization study

Genetically Predicted Circulating Levels of Cytokines and the Risk of Cancer

Genetically predicted 91 circulating inflammatory proteins in relation to risk of urological malignancies: a Mendelian randomization study

Associations of the circulating levels of cytokines with the risk of myeloproliferative neoplasms: a bidirectional mendelian-randomization study

Inflammatory factors and the risk of urolithiasis: a bidirectional Mendelian randomization study

Two-sample Mendelian randomization study reveals no causal relationship between inflammatory bowel disease and urological cancers

Genetically predicted circulating levels of cytokines and the risk of oral cavity and pharyngeal cancer: a bidirectional mendelian-randomization study

Exploration of the causal relationship between inflammatory cytokines and prostate carcinoma: a comprehensive Mendelian randomization study

Exploring causal correlations between inflammatory cytokines and colorectal cancer: A 2-sample Mendelian randomization study

A two-sample Mendelian randomization analysis: causal association between chemokines and pan-carcinoma

Circulating inflammatory cytokines and risk of five cancers: a Mendelian randomization analysis

Exploring causal correlations between circulating levels of cytokines and colorectal cancer risk: A Mendelian randomization analysis

CRP, IL-1α, IL-1β, and IL-6 levels and the risk of breast cancer: a two-sample Mendelian randomization study

Causal Linkage Between Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Two-Sample Mendelian Randomization Analysis

Circulating inflammatory cytokines and risk of idiopathic pulmonary fibrosis: a Mendelian randomization study

Micronutrients and Risks of Three Main Urologic Cancers: A Mendelian Randomization Study

Inflammatory cytokines and their potential role in kidney stone disease: a Mendelian randomization study

Correlation between inflammatory cytokines and the likelihood of developing multiple types of digestive system cancers: A Mendelian randomization study

Understanding bladder cancer risk: Mendelian randomization analysis of immune cell and inflammatory factor influence

Causal associations between gut microbiota and urological tumors: a two-sample mendelian randomization study

Genetically evaluating the causal role of peripheral immune cells in colorectal cancer: a two-sample Mendelian randomization study